Lisboa Sabrina F, Gomes Felipe V, Guimaraes Francisco S, Campos Alline C
Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil; Center of Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, Ribeirão Preto, Brazil.
Department of Neuroscience, University of Pittsburgh , Pittsburgh, PA , USA.
Front Neurol. 2016 Jan 28;7:5. doi: 10.3389/fneur.2016.00005. eCollection 2016.
Psychiatric disorders are one of the leading causes of disability worldwide. Although several therapeutic options are available, the exact mechanisms responsible for the genesis of these disorders remain to be fully elucidated. In the last decade, a body of evidence has supported the involvement of the immune system in the pathophysiology of these conditions. Microglial cells play a significant role in maintaining brain homeostasis and surveillance. Dysregulation of microglial functions has been associated with several psychiatric conditions. Cannabinoids regulate the brain-immune axis and inhibit microglial cell activation. Here, we summarized evidence supporting the hypothesis that microglial cells could be a target for cannabinoid influence on psychiatric disorders, such as anxiety, depression, schizophrenia, and stress-related disorders.
精神疾病是全球致残的主要原因之一。尽管有多种治疗选择，但导致这些疾病发生的确切机制仍有待充分阐明。在过去十年中，大量证据支持免疫系统参与了这些疾病的病理生理学过程。小胶质细胞在维持大脑内环境稳定和监测中发挥着重要作用。小胶质细胞功能失调与多种精神疾病有关。大麻素调节脑-免疫轴并抑制小胶质细胞活化。在此，我们总结了支持以下假说的证据：小胶质细胞可能是大麻素影响精神疾病（如焦虑症、抑郁症、精神分裂症和应激相关障碍）的靶点。
